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Apolipoprotein E Polymorphism and Plasma Cholesterol Response to Probucol 
A. Christine Nestruck, Daniel Bouthillier, Charles F. Sing, and Jean Davignon 
Probucol has been shown to be an effective and well-tolerated cholesterol-lowering drug. However, response in terms of 
cholesterol reduction has been shown to vary significantly among individuals. The purpose of this study was to assess the 
role of apolipoprotein E polymorphism in determining this variation. A retrospective study of 89 hypercholesterolemic type 
II patients who had been treated with probucol (1 g/d) and for whom the apolipoprotein E phenotype was known was 
carried out. The patients were first grouped into those with heterozygous familial hypercholesterolemia (FH) and those 
considered to have other forms of hypercholesterolemia (non-FH). Further subclassification of the individuals in both 
groups as Ila or Ilb, allowed the definition of four diagnostic classes, FH Ila or Ilb and non-FH Ila or Ilb. Among these classes 
there was no significant heterogeneity for the relat%nship between response and age or sex. After correction for 
between-class heterogeneity in duration of probucol treatment, comparison of individuals with the apo E3/3 phenotype 
with those carrying the ~4 allele showed significant differences in cholesterol reduction both absolute change and percent 
change. Further contrasts between diagnostic and apo E genotype stratifications of these data showed that the FH patients 
carrying the d allele had the greatest reduction in cholesterol level. . - 
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A LTHOUGH the efficacy of many lipid-lowering drugs is well-documented, it is also recognized that within the 
same diagnostic class of hyperlipidemia, with both dietary 
and drug therapies, there may be significant interpatient 
variability in response. There are generally no obvious char- 
acteristics of the patient that predict whether the individual 
will be a “responder” or “nonresponder,” the degree of 
response, nor paradoxical increases in low-density lipopro- 
tein cholesterol (LDL-C) which, for example, may occur in 
some patients nonresponsive to clofibrate.“’ It is presumed 
that some of this variation in response is due to a genetic 
predisposition for differential metabolic effects of the lipid- 
lowering intervention. This hypothesis is supported by the 
observation that approximately 50% of the interindividual 
variability in total serum cholesterol levels may be attribut- 
able to genetic influences.4 The human apolipoprotein E (ape 
E) structural gene is polymorphic with three common alleles, 
t2, 63, and t4, coding for three major isoforms.” Evidence 
has accrued that apt E polymorphism influences the levels of 
plasma lipids and lipoproteins,s”’ a striking example being 
that the homozygous E2/2 phenotype (and occasionally E2 
heterozygosity) is necessary, in combination with other 
genetic or nongenetic influences, for the development of 
familial dysbetalipoproteinemia (type III).‘2~‘4 By extension, 
several studies have searched for an influence of the ape E 
gene on the development of atherosclerosis.“-” Additionally, 
from a number of studies of normal individuals apo E has 
been shown to account for 9% to 15% of the normal variabil- 
ity in plasma cholesterol levels; the t2 allele predicting a 
lower and the ~4 allele a higher plasma cholesterol concentra- 
tion.‘8”9 
Probucol has been shown to have a variable efficacy in 
the treatment of hypercholesterolemia type II; the genetic 
classification (monogenic or polygenic) partially predicting 
the degree of LDL-C reduction.” Preliminary evidence had 
suggested to us that patients with the ~4 allele responded 
better, in terms of plasma cholesterol reduction, to 
probucol.” We therefore undertook this retrospective, sys- 
tematic study, using a much larger number of patients, to 
determine whether the lipid-lowering effect of probucol is 
independent of the apolipoprotein E genotype of the patient. 
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MATERIALS AND METHODS 
Subjects 
The clinical records of 13 1 hypercholesterolemic type II patients 
of our lipid clinic who had been given probucol were surveyed. 
Having satisfied the following criteria, 89 were entered into this 
study: the patients had high plasma cholesterol levels and LDL-C 
~190 mg/dL, probucol (lg/d) was the only lipid-lowering drug 
administered and there were no cases with confounding secondary 
factors such as oral synthetic hormone replacement (estrogens or 
thyroxin), ileal bypass, or diabetes. A stable baseline period with the 
patients taking no lipid-lowering drugs but on a prescribed diet, 
appropriate to the hyperlipidemia phenotype, was chosen to include 
the three or four cholesterol measurements that immediately pre- 
ceded the probucol period. In ten cases, however, because other 
therapeutic regimens had been t&d in the interval, this was not 
available and the baseline had been obtained 2.7 f 1.0 years 
previously. In five of these cases, however, one or two cholesterol 
values were available prior to the administration of probucol which 
were very similar to the baseline obtained earlier, or with cessation of 
probucol, cholesterol levels rose to the range of the previously 
obtained baseline. There was no clustering of these ten subjects in 
any of the diagnostic or genotype subgroups: 5 FH, 5 non-FH with 
almost equal distribution of IIa and IIb classifications. Seven 
subjects had the E3/3 phenotype and the three apo E4/3 individuals 
were in the group of subjects for whom at least one cholesterol 
observation was available just prior to institution of probucol treat- 
ment. Further, cholesterol response to probucol was not extreme in 
these ten subjects; all showed moderate reductions. The baseline 
averaged 14 + 6 weeks. In order to have enough determinations to 
assess the effect of probucol, the period of observation was selected 
as the first five or six cholesterol measurements after institution of 
the drug and this averaged 28 + 12 weeks. Dietary therapy 
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Table 1. Clinical Features and Details of the Study Periods 
Hyperlipidsmia n (Males1 
Total 89 (361 
FH Ila 34(11) 
FH Ilb 16 (9) 
Ila 12 (1) 
Ilb 27 (15) 








Weeks on baseline 13.9 2 6.4 
Baseline measurements, n 3.7 ?I 1.2 
Weeks on probucol 27.7 + 11.7 
Probucol measurements, n 5.1 * 2.0 
Values are given as mean + SD. 
continued during the probucol period and was monitored throughout 
by regular consultations with a dietitian and as a routine, by body 
weight fluctuation. 
The diagnosis of familial hypercholesterolemia (FH) was con- 
firmed on the basis of raised cholesterol levels associated with the 
presence of tendon xanthomas (X), which in doubtful cases had been 
confirmed by radiologic examination, or a positive family history for 
premature coronary heart disease and tendon xanthomas in at least 
one first-degree relative. Although many of the type 11 patients had 
been classified as familial combined hyperlipidemia (FCH) due to 
the presence of multiple hyperlipidemic phenotypes within the same 
family, this information was not available for all patients, and 
therefore, this non-FH group included FCH and possibly polygenic 
hypercholesterolemia. *’ Both FH and non-FH type II were subclas- 
sified as Ha or IIb on the basis of baseline plasma triglyceride:cho- 
lesterol ratios of ~0.4 and 20.4, respectively.’ This resulted in four 
diagnostic classes: IIaX and IIbX for FH and Ha and IIb for 
non-FH. The clinical features of the patients and the study periods 
are summarized in Table 1. 
All blood samples were obtained after 12 to 14 hours of fasting 
and drawn into Vacutainer tubes containing EDTA (1 mg/mL). 
Plasma were stored at 4°C until analysis within three to four days. 
As previously described, plasma and lipoprotein lipids were mea- 
sured using an autoanalyser (ABA-loo, Abbott Laboratories) after 
Lipid Research Clinic methods and apolipoprotein E phenotypes 
were determined after isoelectric focusing of VLDL separated and 
washed by ultracentrifugation.*3 
Statistical Methods 
The average levels of cholesterol during the baseline period and 
the period while the patient was on probuwl were the primary 
variables considered. Multiple linear regressior?’ was used to investi- 
gate the contribution of age at the beginning of the probucol 
treatment, number of weeks on baseline, weeks on probucol, number 
of times cholesterol was measured during the baseline and number of 
measurements during the probucol period to interindividual varia- 
tion in these primary variables. The one-way ANOVA was used to 
test for significant differences in the average value of a trait among 
diagnostic classes and apoE genotypes.‘4 Statistical tests were 
judged significant at the .05 level of probability. 
Table 2. Average Age and Weeks on Baseline for Each of the 
Four Subgroups of Patients 
” Age (yr) 
FH Ila 34 43.9 * 13.3 
FH Ilb 16 44.7 + 9.2 
Ila 12 55.0 * 17.2 
Ilb 27 50.9 r 9.8 
F test 3.39 
Probability .02 
Values are given as mean + SD. 
Wwks on Baseline 
13.1 f 6.0 
10.1 .r 5.1 
16.0 f 5.7 




We began our analyses of these data by considering the 
distribution among the diagnostic classes and apo E geno- 
types of age at the beginning of the probucol treatment, 
weeks on baseline, number of measurements during the 
baseline period, weeks on probucol, and the number of 
measurements during the probucol period. We found no 
statistically significant differences among genotypes for the 
average of any of these concomitants. However, the average 
age of the patients and weeks on baseline varied significantly 
among the four diagnostic classes. Table 2 summarizes these 
comparisons. 
The comparison of the average age of patients with FH 
(44.2 years) with that of the non-FH patients (52.1 years) 
explains the major fraction of the variability among diagnos- 
tic classes. The non-FH individuals were followed signifi- 
cantly longer (4 more weeks) during the baseline period than 
those with FH. This difference in length of time, however, 
was not associated with a significant difference in the 
number of measurements during the baseline. 
We next turned to determining whether these concomi- 
tants were associated with individual average cholesterol 
levels during baseline or the probucol periods. Twenty-one 
percent (P < ,001) of the interindividual variability in 
average cholesterol for the baseline period and 8% (P > . IO) 
for the probucol period were associated with variability in 
these five concomitants. As summarized in Table 3, a 
stepwise regression established that weeks on baseline and 
weeks on probucol explain a major fraction of the variability 
in baseline cholesterol, R* = 17.6. Although the effect of 
these predictors on the average cholesterol level during the 
probucol period was not statistically significant, the longer 
that the patient was followed the lower the average choles- 
Table 3. Regression Coefficients for the Relationship Between 
the Dependent Variables, Mean Baseline (B) Cholesterol, and 
Mean Probucol (PB) Cholesterol. and Concomitant Variation 
in Age. Weeks of Treatment, and Number of Observations 
During Each Period 
Baseline Probucol 
Concomitant Cholestwd chdesteml 
Age 0.22 0.20 
Weeks 8 -2.97’ -2.06 
Samples 8 (I-I) - 14.37 -6.25 
Weeks P8 -2.45’ -1.01 
Samples PB (n) 5.68 1.05 
I? 21.03’ 8.3 
*Significantly different from zero at the .O 1 level of probability. 
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Table 4. A Description of the Cholesterol Data CHOLESTEROL mg/dl 
Variable Mean SD Range of Values 
Raw unadjusted date 
Baseline 363.47 74.75 229-598 
Probucol 313.01 65.8 1 195-520 
Change - 50.46 41.65 71-- 144 
% Change _ 13.39 11.00 245-39.0 
Adjusted data 
Baseline 363.47 67.85 206577 
Probucol 313.01 63.38 185-489 
Change -50.46 38.20 61-- 136 
% Change - 13.52 10.34 20.2-- 38.3 
The change variable - the average level during the baseline - the 
average level during the probucol treatment period. 
terol level in both periods. There was no evidence for 
significant heterogeneity (at .lO level of probability) among 
diagnostic classes or among the apoE genotype classes for 
either of the regression equations given in Table 3. 
We next adjusted the individual average cholesterol levels 
during the baseline and during the probucol periods each 
separately for weeks on baseline and weeks on probucol. 
Table 4 presents a description of the unadjusted and adjusted 
data that will be considered below for the analysis of the 
effects of diagnosis and apolipoprotein E genotype on 
response to probucol. After adjustment, the average values 
do not change but the range is narrowed and there are small 
reductions in the standard deviations of each of the four 
variables. A paired t test of the average of the difference 
between individual mean cholesterol levels during baseline 

















All subjects did not respond to probucol with a drop in 
cholesterol. Although 81 patients showed an average 
decrease of 58 mg/dL (adjusted data, 14.6% change), the 
mean plasma cholesterol increased in eight. These records 
were surveyed in detail. All patients showed increases in 
cholesterol and LDL-C and the baseline had been obtained 
immediately before the probucol period. Seven of these 
resistant patients have the E3/3 genotype (four FH type IIa, 
one Ha non-FH and two FH IIb). The other resistant 
individual is E3/2 and type IIa FH. 
Fig 1. Mean plasma cholesterol levels for type II hypercholes- 
terolemic patients on baseline (no lipid-lowering medication) and 
on probucol (1 g/d]. Subjects were subgrouped by diagnosis, 
Familial Hypercholesterolemia IFHI (Ilax + Ilbxj and non-FH (lb + 
Ilb), and by apo E genotype, E3/3 FH bt = 36) and non-FH fn - 221 
and E4/-, (E4/4 + 4/3 + 4/2) FH bt = 111 and non-FH fn = 14). 
For comparison of the adjusted data by genotype and 
diagnostic classification, the one E2/2 and six E3/2 individ- 
uals were not considered because of small sample sizes. We 
include here only the contrast of the most frequent E3/3 
genotypic class (n = 57) with the pooled class of genotypes 
carrying the t4 allele (E4/2 + E4/3 + E4/4, n = 25). There 
were highly significant differences among the diagnostic 
classes at both baseline and during the probucol treatment. 
For the baseline period, patients with FH (IIaX and IIbX) 
had a significantly higher (P < .OOl) average cholesterol 
(388 k 61 mg/dL) than the non-FH group (329 2 58 
mg/dL). The differences between the mean IIaX v IIbX and 
IIa v Mb, during the baseline period or during the probucol 
treatment, were not statistically significant. Despite the 
differences in baseline levels, the average response of the FH 
group (-51 f 39 mg/dL) was not significantly different 
from the average response of the non-FH group (-49 + 37 
mg/dL), - 12.9 and - 15.2%, respectively. 
In considering response by genotype, however, although 
the average baseline cholesterol level of the E4- genotypes 
was not significantly different than the average of the E3/3 
genotypes, there was a highly significant difference between 
genotypes on probucol. This effect is reflected in a signifi- 
cantly larger response for the E4- (-61 k 36 mg/dL, 
-18%) than the E3/3- genotypes (-46 * 39 mg/dL, 
- 12%). Furthermore, as shown in Fig 1, this response is 
dependent on the diagnostic classification. For the patients 
with presumably polygenic hypercholesterolemia and famil- 
ial combined hypercholesterolemia, ie non-FH, the response 
to probucol was not significantly different between geno- 
types, the E3/3 and E4- groups showing similar reductions, 
-47 and - 54 mg/dL change, - 14% and - 16% respec- 
tively, P > .50. In contrast, for those with FH, the drop in 
cholesterol was significantly greater in those subjects with 
the E4 allele (- 70 + 39 mg/dL, - 18%) than in those with 
the E3/3 genotype (-45 + 39 mg/dL, - 11%) P -C .03. 
DISCUSSION 
This retrospective study confirms and extends the observa- 
tions of previous trials2~3~M~ZS-2g in which probucol was shown 
to be a moderately effective cholesterol lowering agent in 
diet-resistant hyperlipidemia type II with significant inter- 
patient variability in response. In an attempt to investigate 
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genetic factors which may play a role in this variability, we 
first subdivided the patients into two groups; those with 
clearly defined familial hypercholesterolemia and those with 
FCH or hypercholesterolemia of undefined polygenic etiolo- 
gy, or non-FH. The FH patients were found to be younger 
and were followed an average of 4 weeks less during the 
baseline period. Both groups were found to have significantly 
elevated cholesterol levels at baseline, and notwithstanding 
the higher baseline cholesterol levels of the FH group during 
baseline, both FH and non-FH groups responded to probucol 
with an average drop of approximately 50 mg/dL, again with 
significant interpatient variability and with no differences 
between the IIa or IIb subclassifications. For the eight 
patients whose cholesterol and LDL-C levels showed an 
average rise with probucol, five had been diagnosed as FH 
IIa, two as FH IIb, and one as IIa non-FH. 
Whdn response was considered in terms of apo E genotype, 
however, the genotypes with the ~4 allele were found to have 
a significantly greater reduction in cholesterol level than the 
E3/3 genotype. Furthermore, when diagnostic classification 
was considered in addition to apo E genotype, this effect was 
shown to be due to the significantly greater response of the 
FH patients having the d allele; E3/3 FH, non-FH patients 
with the ~4 allele and the non-FH E3/3 patients all 
responding with smaller reductions in cholesterol level. 
This study was not designed to investigate changes in 
cholesterol associated with the individual lipoprotein classes. 
However, in view of the lowering effect of probucol on both 
LDL and HDL cholesterol,26*27 we were interested in the 
contribution of potential reductions in HDL-C to the 
observed overall changes in plasma cholesterol levels. We 
were able to obtain one or two lipoprotein cholesterol profiles 
in both the baseline and probucol periods for 30 of the 82 
subjects whose cholesterol values were considered in the 
contrasts of genotype by diagnostic classification: in the FH 
group, 11135 E3/3 and 5111 E4/-, and in the non-FH 
group, 8/ 22 E3 / 3 and 6/ 14 E4/ - individuals. The initial 
HDL-C levels for all subjects were low and the changes 
observed were similar in all sub-groups: -3 1 i 16% from 
43 k 8 mg/dL for the FH E3/3 subjects, -33 + 13% from 
40 + 12 mg/dL for the FH E4/ - patients, - 33 ? 23% from 
42 f 9 mg/dL for the non-FH E3/3 subjects and - 27 + 14% 
from 41 _t 8 mg/dL for the non-FH E4/ - patients. Thus, in 
this study, the response of total cholesterol to probucol and 
the differences attributed to genotypic and diagnostic classi- 
fication appear to reflect changes in LDL-C. 
In previous studies of response to probucol, attempts have 
been made to explain variability in response on the basis of 
diagnostic classification of the hyperlipidemia2*20~27~29 with 
only partial success. This study clearly demonstrates that the 
nature of the response to probucol depends on the genetic 
determination of the hypercholesterolemia as well as the 
apolipoprotein E genotype. The mechanisms underlying this 
association are at best speculative. 
Current evidence, from the findings of Baker et a13’ that 
homozygous, receptor-negative FH patients respond well to 
probucol with lowered LDL cholesterol levels and regression 
of xanthomas and the findings of Naruszewicz et al” that 
receptor-deficient WHHL rabbits treated with probucol 
show substantial reductions in LDL cholesterol and an 
increased catabolic rate of LDL, suggests that one of the 
possible modes of action of probucol does not involve the 
LDL receptor, the genetic defect in FH. A receptor- 
mediated process may also, however, be superimposed on this 
mode of action.*’ Again, the studies using fibroblasts from 
both WHHL and normal rabbits and in vivo injections of 
LDL from probucol treated animals, demonstrated an 
increased uptake and degradation of LDL from probucol 
treated animals by the high affinity LDL receptor possibly 
due to a chemically induced change in the LDL molecules.” 
Probucol is a unique lipid-lowering agent due to its sulfur- 
containing lipophilic properties,32 and it is a powerful antioxi- 
dant estimated to be more potent than vitamin E.33 Further, 
it was recently reported that probucol added to in vitro 
incubations of LDL with endothelial cells is a highly effective 
inhibitor of cell-mediated oxidation of LDL and thus directs 
catabolism away from the macrophage pathway.34S3s The 
observed regression in xanthomas3’ further supports the 
premise that this action is also independent of the acetyl- 
LDL-receptor of the macrophages. Thus, it is likely that 
probucol enhances the metabolism of LDL by mechanisms 
independent of the native or modified-LDL receptor. 
Apolipoprotein E is a major determinant responsible for 
mediating the high affinity binding of lipoproteins to the 
LDL receptor as well as the hepatic apo E receptor.36 The 
major isoforms are known to differ in their ability to interact 
with these receptors; the E2 form and various E2 mutants 
having as little as 2% of the normal E3 binding36 which 
results in varying degrees of decreased remnant catabolism. 
The E4 isoform has equivalent binding to E3; the structural 
modification of an additional positively charged residue in 
E4 at site 112 having no apparent effect on binding.36 
Recently, however, it has been reported that E4 VLDL is 
catabolized more rapidly in E3/3 individuals and indepen- 
dently of the LDL receptor.37 Thus, taken with the probucol 
induced chemical modifications of LDL which result in an 
altered and enhanced LDL catabolism, it is possible that an 
additionally enhanced catabolism of VLDL, both processes 
being independent of the LDL receptor, explains the greater 
response of FH-~4 carrying individuals in the present study. 
A presumption being that in the face of defective receptors 
(FH), the role of apo E possibly as a determinant of 
lipoprotein conformation” is crucial in determining lipopro- 
tein metabolism. That the non-FH individuals did not 
respond as well can be explained by the fact that the 
underlying genetic etiology of their disease involves many 
gene loci rather than a monogenic receptor defect. The 
polygenic nature of the non-FH hypercholesterolemia likely 
masks the apo E response that is observed in FH patients. 
The use of probucol as a probe provides further evidence for 
the role of genetic factors in determining the homeostasis 
that establishes individual serum cholesterol levels. Genetic 
factors must be considered in our efforts to understand the 
mechanism(s) of action of probucol and in our selection of 
intervention strategies to lower an individual’s cholesterol 
level. 
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